Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
BeOne Medicines AG
ONC·Healthcare
B ★★★Hold
Current$406.96
Target$443.39
Return+9.0%
Nov 8, 2026

BeOne Medicines combines rapid BRUKINSA-led oncology growth with improving profitability and substantial cash generation, but flagship-product concentration and demanding valuation limit its margin of safety.

Score
72
Rockwell Automation, Inc.
ROK·Industrials
B ★★★Hold
Current$375.86
Target$405.00
Return+7.8%
Nov 8, 2026

Rockwell Automation combines durable industrial switching costs, high-margin control software, and strong cash generation, but its premium valuation and cyclical factory spending limit near-term upside.

Score
72
Versigent PLC
VGNT·Consumer Discretionary
B ★★★Hold
Current$40.96
Target$53.83
Return+31.4%
Nov 7, 2026

Versigent offers low-cost exposure to growing vehicle electrical content and improving manufacturing profitability, but concentrated OEM customers, automotive cyclicality, and post-spin debt may constrain sustainable shareholder returns.

Score
72
Murphy Oil Corporation
MUR·Energy
B ★★★Hold
Current$35.96
Target$38.80
Return+7.9%
Nov 7, 2026

Murphy Oil offers low operating-earnings multiples and new offshore production opportunities, but commodity-price dependence and heavy capital spending limit near-term free cash flow and investment conviction.

Score
72
Sezzle Inc.
SEZL·Financials
B ★★★Hold
Current$149.43
Target$172.80
Return+15.6%
Nov 7, 2026

Sezzle combines rapid subscriber growth, expanding financial products, and strong profitability, but its valuation, credit-cycle exposure, and competitive pressures limit the margin of safety.

Score
72
Datadog, Inc.
DDOG·Technology
B ★★★Hold
Current$179.04
Target$201.92
Return+12.8%
Nov 7, 2026

Datadog offers durable cloud observability growth, expanding AI-driven demand, and strong cash generation, but premium valuation multiples, stock-based compensation, and competitive pressure constrain near-term upside.

Score
72
Madrigal Pharmaceuticals, Inc.
MDGL·Healthcare
B ★★★Hold
Current$400.10
Target$492.90
Return+23.2%
Nov 6, 2026

Madrigal's rapidly expanding Rezdiffra franchise offers substantial long-term MASH treatment growth and improving profitability, but single-product concentration, competition and unresolved clinical-data allegations create significant downside risk.

Score
72
Corcept Therapeutics Incorporated
CORT·Healthcare
B ★★★Hold
Current$71.63
Target$92.40
Return+29.0%
Nov 6, 2026

Corcept's rapidly scaling Lifyorli franchise and profitable endocrine business create substantial growth potential, but regulatory uncertainty and dependence on ambitious future earnings expansion limit the margin of safety.

Score
72
Par Pacific Holdings, Inc.
PARR·Energy
B ★★★Hold
Current$68.69
Target$81.11
Return+18.1%
Nov 6, 2026

Par Pacific offers attractive exposure to geographically advantaged refining assets, strong cash generation, and shareholder returns, but its earnings remain vulnerable to refining-margin normalization and regulatory uncertainty.

Score
72
American International Group, Inc.
AIG·Financials
B ★★★Hold
Current$80.93
Target$88.00
Return+8.7%
Nov 6, 2026

AIG combines profitable global insurance underwriting with substantial shareholder returns and potential earnings growth, but catastrophe volatility and its elevated historical book-value multiple constrain the margin of safety.

Score
72
Equitable Holdings, Inc.
EQH·Financials
B ★★★Hold
Current$56.12
Target$60.80
Return+8.3%
Nov 5, 2026

Equitable combines resilient retirement earnings, asset-management exposure and merger synergy potential, but integration uncertainty and a valuation near its historical upper range constrain the margin of safety.

Score
72
Fabrinet
FN·Technology
B ★★★Hold
Current$341.64
Target$440.00
Return+28.8%
Nov 5, 2026

Fabrinet benefits from structural growth in AI data-center optical networking and strong manufacturing returns, but customer concentration, rising capital intensity, and negative free cash flow limit near-term investment conviction.

Score
72